BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 19648788)

  • 1. Analysis of infectious complications in infants with acute lymphoblastic leukemia treated on the Children's Cancer Group Protocol 1953: a report from the Children's Oncology Group.
    Salzer W; Dinndorf P; Dreyer Z; Hilden J; Reaman GH
    J Pediatr Hematol Oncol; 2009 Jun; 31(6):398-405. PubMed ID: 19648788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased induction morbidity and mortality following modification to induction therapy in infants with acute lymphoblastic leukemia enrolled on AALL0631: a report from the Children's Oncology Group.
    Salzer WL; Jones TL; Devidas M; Dreyer ZE; Gore L; Winick NJ; Sung L; Raetz E; Loh ML; Wang CY; De Lorenzo P; Valsecchi MG; Pieters R; Carroll WL; Hunger SP; Hilden JM; Brown P
    Pediatr Blood Cancer; 2015 Mar; 62(3):414-8. PubMed ID: 25407157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modifications to induction therapy decrease risk of early death in infants with acute lymphoblastic leukemia treated on Children's Oncology Group P9407.
    Salzer WL; Jones TL; Devidas M; Hilden JM; Winick N; Hunger S; Carroll WL; Camitta B; Dreyer ZE
    Pediatr Blood Cancer; 2012 Nov; 59(5):834-9. PubMed ID: 22488662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group.
    Reaman GH; Sposto R; Sensel MG; Lange BJ; Feusner JH; Heerema NA; Leonard M; Holmes EJ; Sather HN; Pendergrass TW; Johnstone HS; O'Brien RT; Steinherz PG; Zeltzer PM; Gaynon PS; Trigg ME; Uckun FM
    J Clin Oncol; 1999 Feb; 17(2):445-55. PubMed ID: 10080584
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report from the Children's Cancer Group.
    Nachman J; Sather HN; Gaynon PS; Lukens JN; Wolff L; Trigg ME
    J Clin Oncol; 1997 Jun; 15(6):2222-30. PubMed ID: 9196134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intensified PEG-L-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: a report from the Children's Oncology Group.
    Salzer WL; Devidas M; Shuster JJ; Wang C; Chauvenet A; Asselin BL; Camitta BM; Kurtzberg J;
    J Pediatr Hematol Oncol; 2007 Jun; 29(6):369-75. PubMed ID: 17551397
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intensified therapy for infants with acute lymphoblastic leukemia: results from the Dana-Farber Cancer Institute Consortium.
    Silverman LB; McLean TW; Gelber RD; Donnelly MJ; Gilliland DG; Tarbell NJ; Sallan SE
    Cancer; 1997 Dec; 80(12):2285-95. PubMed ID: 9404706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic strategies for childhood high-risk acute lymphoblastic leukemia].
    Lu XT
    Beijing Da Xue Xue Bao Yi Xue Ban; 2013 Apr; 45(2):327-32. PubMed ID: 23591360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment related deaths during induction and in first remission in acute lymphoblastic leukaemia: MRC UKALL X.
    Wheeler K; Chessells JM; Bailey CC; Richards SM
    Arch Dis Child; 1996 Feb; 74(2):101-7. PubMed ID: 8660070
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Infection-related complications during treatment for childhood acute lymphoblastic leukemia.
    Inaba H; Pei D; Wolf J; Howard SC; Hayden RT; Go M; Varechtchouk O; Hahn T; Buaboonnam J; Metzger ML; Rubnitz JE; Ribeiro RC; Sandlund JT; Jeha S; Cheng C; Evans WE; Relling MV; Pui CH
    Ann Oncol; 2017 Feb; 28(2):386-392. PubMed ID: 28426102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group.
    Nachman JB; La MK; Hunger SP; Heerema NA; Gaynon PS; Hastings C; Mattano LA; Sather H; Devidas M; Freyer DR; Steinherz PG; Seibel NL
    J Clin Oncol; 2009 Nov; 27(31):5189-94. PubMed ID: 19805689
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improving infectious adverse event reporting for children and adolescents enrolled in clinical trials for acute lymphoblastic leukemia: A report from the Children's Oncology Group.
    Elgarten CW; Thompson JC; Angiolillo A; Chen Z; Conway S; Devidas M; Gupta S; Kairalla JA; McNeer JL; O'Brien MM; Rabin KR; Rau RE; Rheingold SR; Wang C; Wood C; Raetz EA; Loh ML; Alexander S; Miller TP
    Pediatr Blood Cancer; 2022 Nov; 69(11):e29937. PubMed ID: 36083863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Infections during induction therapy of protocol CCLG-2008 in childhood acute lymphoblastic leukemia: a single-center experience with 256 cases in China.
    Li SD; Chen YB; Li ZG; Wu RH; Qin MQ; Zhou X; Jiang J; Zhang RD; Xie J; Ma XL; Zhang R; Wang B; Wu Y; Zheng HY; Wu MY
    Chin Med J (Engl); 2015 Feb; 128(4):472-6. PubMed ID: 25673448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infectious complications in children with acute lymphoblastic leukemia and T-cell lymphoma--a rationale for tailored supportive care.
    Lex C; Körholz D; Kohlmüller B; Bönig H; Willers R; Kramm CM; Göbel U
    Support Care Cancer; 2001 Oct; 9(7):514-21. PubMed ID: 11680831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group.
    Mattano LA; Sather HN; Trigg ME; Nachman JB
    J Clin Oncol; 2000 Sep; 18(18):3262-72. PubMed ID: 10986059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurodevelopmental outcome of infants with acute lymphoblastic leukemia: a Children's Cancer Group report.
    Kaleita TA; Reaman GH; MacLean WE; Sather HN; Whitt JK
    Cancer; 1999 Apr; 85(8):1859-65. PubMed ID: 10223582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardioprotection and Safety of Dexrazoxane in Patients Treated for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Advanced-Stage Lymphoblastic Non-Hodgkin Lymphoma: A Report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404.
    Asselin BL; Devidas M; Chen L; Franco VI; Pullen J; Borowitz MJ; Hutchison RE; Ravindranath Y; Armenian SH; Camitta BM; Lipshultz SE
    J Clin Oncol; 2016 Mar; 34(8):854-62. PubMed ID: 26700126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between high vascular endothelial growth factor-A serum levels and treatment outcome in patients with standard-risk acute lymphoblastic leukemia: a report from Children's Oncology Group Study CCG-1962.
    Avramis IA; Panosyan EH; Dorey F; Holcenberg JS; Avramis VI;
    Clin Cancer Res; 2006 Dec; 12(23):6978-84. PubMed ID: 17145817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alpha hemolytic streptococcal infection during intensive treatment for acute myeloid leukemia: a report from the Children's cancer group study CCG-2891.
    Gamis AS; Howells WB; DeSwarte-Wallace J; Feusner JH; Buckley JD; Woods WG
    J Clin Oncol; 2000 May; 18(9):1845-55. PubMed ID: 10784625
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Infectious profile in children with ALL during chemotherapy: A report of study group for infections.
    Zawitkowska J; Drabko K; Szmydki-Baran A; Zaucha-Prażmo A; Lejman M; Czyżewski K; Zalas-Więcek P; Gryniewicz-Kwiatkowska O; Czajńska-Deptuła A; Kulicka E; Semczuk K; Hutnik Ł; Chełmecka-Wiktorczyk L; Klepacka J; Frączkiewicz J; Salamonowicz M; Tomaszewska R; Zając-Spychała O; Irga-Jaworska N; Bień E; Płonowski M; Bartnik M; Ociepa T; Pierlejewski F; Woszczyk M; Gamrot-Pyka Z; Małas Z; Urbanek-Dądela A; Stolpa W; Musiał J; Styczyński J
    J Infect Chemother; 2019 Oct; 25(10):774-779. PubMed ID: 31101529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.